Open-label Brexpiprazole fMRI Trial in Adults With Major Depressive Disorder and Anxiety
Status:
Not yet recruiting
Trial end date:
2023-04-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to use fMRI to evaluate the effects of brexpiprazole as add-on
therapy to antidepressants on brain connectivity in individuals with MDD and symptoms of
anxiety, aged 18 to 65.
Phase:
Phase 4
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.